90%Confidence
0Views
FDASource
2026-04-20Date
Summary
Fresenius Kabi's recall of a common saline solution due to sterility issues highlights systemic manufacturing problems. This could disrupt hospital supply chains and lead to increased regulatory oversight for the company.
Actionable: Evaluate exposure to Fresenius Kabi in healthcare portfolios and consider the risk of further recalls.
AI Confidence: 90%
Data Points
firmFresenius Kabi USA, LLC
classificationClass II
statusOngoing
distributionUS Nationwide , Alaska, and Puerto Rico.
product0.9% Sodium Chloride Injection, USP, (2,250 mg per 250 mL) (9 mg per mL) 250 mL in a 250 mL freeflex bag, Rx only, Fresenius Kabi USA, LLC ("Fresenius
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now